Histogen's FINAL Phase I/IIa Results (2013)

[goldbondmafia]

So I guess everyone has mixed reactions to Histogens results? I think they are taking a step in the right direction personally

[Pentarou]

I know fin loses effectiveness after 7 or so years.

Not true.

http://www.bernsteinmedical.com/research/10-year-finasteride-study-first-to-investigate-long-term-effects-and-safety/

[Purple Glow]

I am very happy with these results.

I am not bald but I am thinning. At a minimum, I want a product that will:

1. Stop my hair loss.
2. Add more terminal hairs.
3. Allow me to continue to fill in any problem spots using Nanogen.

These results meet my minimum criteria, and it sounds like only 1-2 trips for injections per year. I'll take that and be happy.

[Javert]

Also not complacent.. I'm scared shitless. I'm just going for an HT soon for my hairline and waiting on CB.. I just want to trust what i'm doing to my body.

If the sides of fin were mild pain every now and then.. or like.. muscle cramps.. or occasional dry mouth I wouldn't give a shit...

But loss of libido and ED.. not worth it

What exactly is CB?

[Vox]

What exactly is CB?

It stands for cumulonimbus. You put your head under it, you get some lightning and your hair will regrow! Plus, the highly ionized water pouring down will help you to maintain your new hair!

Seriously, there are some older threads here discussing it. As of now, it is an experimental drug.

[Javert]

Thanks.

[inkt2002]

This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.

[KO1]

I don't think this is good advice. As Fin and Dut are dangerous. I'd never reccomend anyone take them.

I don't like the whole "I can handle fin" because even when people say they can you don't know how it's going to react with your endocrine system. Even if it seemingly doesn't do anything you won't know until it's too late.

I guess I just don't agree with pills that have such side effects. It's not worth it to me. Even if I responded well. I took fin for 3 weeks.. and was just too scared to continue.

My penis is worth more than my hair. Always will be. And I'm not even willing to give any % of a risk for it.

I don't know shit.

The boldest part is the only correct statement here.

This is the stupidest piece of advice a young man could ever get. This guy literally knows nothing about this drug, didn't get side effects himself, and now wants to discourage other people from taking the drug. Absolute dumbf**k.

If you're a young man losing his hair, you need to get on medications, and those can be fin, dut, or RU.

Go to www dot twinshairloss dot com. Then decide which twin you want to be.

[clandestine]

My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.

Your guess is worthless.
Less so, even.

[UK_]

This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.

Riiight.. great.. and you are?

[Thinning87]

This is a game changer. The likely start of a death spiral for Histogen. Coming from the VC world, it is quite common for bio start-ups to seek "surplus" funding right before phase results will be disseminated to public for two main reasons- capital raising prior to valuation erosion and capital sought for marketing/product launch which would have a difficult time getting raised with marginal results indicated. My guess is that cash will be depleted before Histogen can/will improve product or can hit market with a marginal product. ETA on marketable product obviously pushed back as well.

these are not marginal results Mr. "Kleiner Perkins".... if you're going to come on an anonymous thread and act like you know something, at least do some research prior to giving a rating on a company in a market you know nothing about.

[inkt2002]

these are not marginal results Mr. "Kleiner Perkins".... if you're going to come on an anonymous thread and act like you know something, at least do some research prior to giving a rating on a company in a market you know nothing about.

Don't need to be an expert of an industry, rather an expert of the VC world to know whats going on. Whenever a company tries to jam through "surplus funding" right before phase results, you know a dark cloud is on the horizon. Try to raise as much capital at baseline valuation right before valuation takes a hit. Seen it way too many times before. They call it the death spiral.
Good luck.

[clandestine]

Right.

To reiterate, your opinion is worthless.

[inkt2002]

Right.

To reiterate, your opinion is worthless.

Hopefully they come to you for funding.

[clandestine]

Hopefully they come to you for funding.